- Home
- BANL vs CVKD Comparison
BANL vs CVKD Comparison
Compare BANL & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANL
- CVKD
- Stock Information
- Founded
- BANL 2015
- CVKD 2022
- Country
- BANL Malaysia
- CVKD United States
- Employees
- BANL N/A
- CVKD N/A
- Industry
- BANL Oil Refining/Marketing
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BANL Energy
- CVKD Health Care
- Exchange
- BANL Nasdaq
- CVKD Nasdaq
- Market Cap
- BANL 22.8M
- CVKD 20.8M
- IPO Year
- BANL 2023
- CVKD 2023
- Fundamental
- Price
- BANL $0.89
- CVKD $16.17
- Analyst Decision
- BANL
- CVKD Strong Buy
- Analyst Count
- BANL 0
- CVKD 2
- Target Price
- BANL N/A
- CVKD $46.00
- AVG Volume (30 Days)
- BANL 8.9K
- CVKD 79.1K
- Earning Date
- BANL 09-12-2024
- CVKD 11-07-2024
- Dividend Yield
- BANL N/A
- CVKD N/A
- EPS Growth
- BANL N/A
- CVKD N/A
- EPS
- BANL N/A
- CVKD N/A
- Revenue
- BANL $521,173,543.00
- CVKD N/A
- Revenue This Year
- BANL N/A
- CVKD N/A
- Revenue Next Year
- BANL N/A
- CVKD N/A
- P/E Ratio
- BANL N/A
- CVKD N/A
- Revenue Growth
- BANL 24.34
- CVKD N/A
- 52 Week Low
- BANL $0.55
- CVKD $5.40
- 52 Week High
- BANL $1.79
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- BANL 44.04
- CVKD 61.78
- Support Level
- BANL $0.77
- CVKD $10.65
- Resistance Level
- BANL $0.91
- CVKD $12.25
- Average True Range (ATR)
- BANL 0.05
- CVKD 1.68
- MACD
- BANL -0.00
- CVKD 0.32
- Stochastic Oscillator
- BANL 54.55
- CVKD 76.54
About BANL CBL International Limited
CBL International Ltd is a company that provides a complete range of marine fuel logistics services. It sources the highest quality marine fuel from its trusted suppliers and ensures timely delivery to its customers. The company's expertise lies in providing a seamless and efficient one-stop solution for vessel refueling needs, making it a reliable partner for shipping companies. CBL International Ltd has a strong presence in China, Hong Kong, and Malaysia.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.